^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NY-ESO-1 Iscomatrix

    i
    Associations
    News

    Trials

    Company:
    CSL Behring, Ludwig Institute for Cancer Research
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma (NCT00518206)
    Phase 2
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/25/2022
    Initiation :
    11/28/2003
    Primary completion :
    01/22/2010
    Completion :
    01/22/2010
    CD8 • CTAG1B • CD4 • CTAG2
    |
    cyclophosphamide • NY-ESO-1 Iscomatrix • cyclophosphamide intravenous
    Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma (NCT00199901)
    Phase 2
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/11/2022
    Initiation :
    09/01/2005
    Primary completion :
    12/01/2008
    Completion :
    12/01/2011
    CTAG1B
    |
    NY-ESO-1 Iscomatrix